- Home
- IRT vs TGTX Comparison
IRT vs TGTX Comparison
Compare IRT & TGTX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- IRT
- TGTX
- Stock Information
- Founded
- IRT 2009
- TGTX 1993
- Country
- IRT United States
- TGTX United States
- Employees
- IRT N/A
- TGTX N/A
- Industry
- IRT Real Estate Investment Trusts
- TGTX Biotechnology: Pharmaceutical Preparations
- Sector
- IRT Real Estate
- TGTX Health Care
- Exchange
- IRT Nasdaq
- TGTX Nasdaq
- Market Cap
- IRT 4.0B
- TGTX 4.2B
- IPO Year
- IRT 2013
- TGTX 1995
- Fundamental
- Price
- IRT $17.18
- TGTX $31.75
- Analyst Decision
- IRT Strong Buy
- TGTX Strong Buy
- Analyst Count
- IRT 9
- TGTX 4
- Target Price
- IRT $22.11
- TGTX $42.50
- AVG Volume (30 Days)
- IRT 2.3M
- TGTX 2.0M
- Earning Date
- IRT 10-29-2025
- TGTX 11-03-2025
- Dividend Yield
- IRT 3.98%
- TGTX N/A
- EPS Growth
- IRT N/A
- TGTX N/A
- EPS
- IRT 0.12
- TGTX 0.36
- Revenue
- IRT $645,404,000.00
- TGTX $454,069,000.00
- Revenue This Year
- IRT $5.15
- TGTX $82.58
- Revenue Next Year
- IRT $5.60
- TGTX $44.99
- P/E Ratio
- IRT $142.06
- TGTX $87.91
- Revenue Growth
- IRT N/A
- TGTX 30.96
- 52 Week Low
- IRT $16.59
- TGTX $21.16
- 52 Week High
- IRT $22.26
- TGTX $46.48
- Technical
- Relative Strength Index (RSI)
- IRT 43.80
- TGTX 54.67
- Support Level
- IRT $17.30
- TGTX $31.34
- Resistance Level
- IRT $18.18
- TGTX $32.56
- Average True Range (ATR)
- IRT 0.34
- TGTX 1.09
- MACD
- IRT -0.05
- TGTX 0.45
- Stochastic Oscillator
- IRT 10.31
- TGTX 68.33
About IRT Independence Realty Trust Inc.
Independence Realty Trust Inc is a real estate investment trust (REIT) that acquires, owns, operates, improves and manages multifamily apartment communities across non-gateway U.S. markets. It owns and operates multifamily apartment properties, across non-gateway U.S markets, including Louisville, Memphis, Atlanta, and Raleigh. The company is focused on gaining scale within key amenity-rich submarkets that offer school districts, retail, and various employment centers.
About TGTX TG Therapeutics Inc.
TG Therapeutics Inc is a fully integrated, commercial-stage, biopharmaceutical company focused on the acquisition, development, and commercialization of novel treatments for B-cell diseases. The company has received approval from the U.S. Food and Drug Administration (FDA) for BRIUMVI (ublituximab-xiiy) for the treatment of adult patients with relapsing forms of multiple sclerosis (RMS). In addition, it is developing TG-1701 (BTK inhibitor), Azer-Cel (allogeneic CD19 CAR T), and TG-1801 (anti-CD47/CD19 bispecific mAb) for B-cell disorders, which are under Phase 1 trials. Geographically, the company generates a majority of its revenue selling BRIUMVI in the United States, with the rest coming from sales in other countries.